« ОСОБЕННОСТИ КОСТНОГО МЕТАБОЛИЗМА У БОЛЬНЫХ С ДИАБЕТИЧЕСКОЙ ОСТЕОАРТРОПАТИЕЙ РАЗЛИЧНЫХ СТАДИЙ»
Abstract
Сахарный диабет 2 типа ( СД 2) является метаболическим расстройством с самой высокой распространенностью и заболеваемостью во всем мире.
References
1. Vestergaard P., Rejnmark L., Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia. 2005;48:1292–1299. doi: 10.1007/s00125-005-1786-3. [PubMed] [CrossRef] [Google Scholar]
2. Retzepi M., Donos N. The effect of diabetes mellitus on osseous healing. Clin. Oral Implants Res. 2010;21:673–681. doi: 10.1111/j.1600-0501.2010.01923.x. [PubMed] [CrossRef] [Google Scholar]
3. Hernandez R.K., Do T.P., Critchlow C.W., Dent R.E., Jick S.S. Patient-related risk factors for fracture-healing complications in the United Kingdom General Practice Research Database. Acta Orthop. 2012;83:653–660. doi: 10.3109/17453674.2012.747054. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
4. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis. Osteoporos. Int. 2007;18:427–444. doi: 10.1007/s00198-006-0253-4. [PubMed] [CrossRef] [Google Scholar]
5. Picke A.K., Campbell G., Napoli N., Hofbauer L.C., Rauner M. Update on the impact of type 2 diabetes mellitus on bone metabolism and material properties. Endocrinol. Connect. 2019;8:R55–R70. doi: 10.1530/EC-18-0456. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
6. Lauterbach S., Kostev K., Kohlmann T. Prevalence of diabetic foot syndrome and its risk factors in the UK. J. Wound Care. 2010;19:333–337. doi: 10.12968/jowc.2010.19.8.77711. [PubMed] [CrossRef] [Google Scholar]
7. Pscherer S., Dippel F.W., Lauterbach S., Kostev K. Amputation rate and risk factors in type 2 patients with diabetic foot syndrome under real-life conditions in Germany. Prim Care Diabetes. 2012;6:241–246. doi: 10.1016/j.pcd.2012.02.004. [PubMed] [CrossRef] [Google Scholar]
8. Kahm K., Laxy M., Schneider U., Rogowski W.H., Lhachimi S.K., Holle R. Health care costs associated with incident complications in patients with type 2 diabetes in Germany. Diabetes Care. 2018;41:971–978. doi: 10.2337/dc17-1763. [PubMed] [CrossRef] [Google Scholar]
9. Prasad R.B., Groop L. Precision medicine in type 2 diabetes. J. Intern Med. 2019;285:40–48. doi: 10.1111/joim.12859. [PubMed] [CrossRef] [Google Scholar]
10. Ehnert S., Rinderknecht H., Aspera-Werz R.H., Haussling V., Nussler A.K. Use of in vitro bone models to screen for altered bone metabolism, osteopathies, and fracture healing: Challenges of complex models. Arch. Toxicol. 2020;94:3937–3958. doi: 10.1007/s00204-020-02906-z. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
